Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich area will see the first major innovation due to SandboxAQ and NVIDIA's AI-driven chemistry breakthrough by the end of 2024?
Drug Discovery • 25%
Materials Design • 25%
Chemical Engineering • 25%
Other • 25%
Official announcements from companies, major news outlets
In July 2024, SandboxAQ and NVIDIA Accelerate AI-Driven Chemistry by 80x
Jul 26, 2024, 02:20 PM
In July 2024, SandboxAQ announced a significant breakthrough in AI-driven chemistry by collaborating with NVIDIA. The partnership leverages SandboxAQ's large quantitative models (LQMs) and NVIDIA's CUDA-accelerated Density Matrix Renormalization Group (DMRG) algorithm. This combination accelerates computational chemistry calculations by more than 80 times. The enhanced speed is expected to have a substantial impact on high-impact areas such as drug discovery and materials design, where data is often limited. CEO Nadia Harhen highlighted the potential of these advancements to revolutionize simulations in these fields.
View original story
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Infectious disease treatment • 25%
Other • 25%
Cryptography • 25%
Material Science • 25%
Artificial Intelligence • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Healthcare • 25%
Finance • 25%
Energy • 25%
Other • 25%
Cancer treatment • 25%
Neurodegenerative disease treatment • 25%
Cardiovascular disease treatment • 25%
Other • 25%
AI in materials science • 25%
AI in drug discovery • 25%
AI in environmental science • 25%
Other • 25%
Artificial Intelligence • 25%
Pharmaceuticals • 25%
Energy • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Healthcare • 25%
Finance • 25%
Energy • 25%
Technology • 25%
Biotechnology • 25%
Physics • 25%
Chemistry • 25%
Other • 25%
Automotive • 25%
Aerospace • 25%
Healthcare • 25%
Energy • 25%
Healthcare • 25%
Finance • 25%
Retail • 25%
Manufacturing • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Moderna • 25%